Amarin Corp Plc - Company Profile

Powered by

All the data and insights you need on Amarin Corp Plc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Amarin Corp Plc Strategy Report

  • Understand Amarin Corp Plc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Amarin Corp Plc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

Amarin Corp Plc (Amarin) is a pharmaceutical company which develops and commercializes medicines for cardiovascular diseases. The company's lead product, Vascepa (icosapent ethyl), is a single-molecule prescription capsule used as an adjunct to diet for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia and cardiovascular risk. Amarin is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. The company markets the product in the US through wholesalers and specialty pharmacy providers. The company has operations in Ireland, the US, Germany, Switzerland, the Uk, Italy, France and Israel. Amarin is headquartered at Dublin, Ireland.

 Gain a 360-degree view of Amarin Corp Plc and make more informed decisions for your business Gain a 360-degree view of Amarin Corp Plc and make more informed decisions for your business Find out more
Headquarters Ireland
Address 88 Harcourt Street, Dublin
Website www.amarincorp.com
Telephone 353 1 6699020
No of Employees 275
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange AMRN (NASD)
Revenue (2022) $306.9M -16.9% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 44.1% (2022 vs 2021)
Market Cap* $361.6M
Net Profit Margin (2022) XYZ 32.8% (2022 vs 2021)
* As of and is in US$
View Amarin Corp Plc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Amarin Corp Plc premium industry data and analytics

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

20+

Clinical Trials

Determine Amarin Corp Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Amarin Corp Plc’s relevant decision makers and contact details.

16+

Catalyst Calendar

Proactively evaluate Amarin Corp Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

9

Pipeline Drugs

Identify which of Amarin Corp Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Marketed Drugs

Understand Amarin Corp Plc’s commercialized product portfolio to stay one step ahead of the market.

1

Sales & Consensus Forecasts

Understand the current and future drug revenue for Amarin Corp Plc and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Amarin Corp Plc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Vascepa Capsules Vascepa
Pipeline Programs:
Vascepa:
XYZ
XYZ
XYZ
Understand Amarin Corp Plc portfolio and identify potential areas for collaboration Understand Amarin Corp Plc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In August, the company entered into a marketing and commercialization agreement with Neopharm Israel for VAZKEPA (icosapent ethyl) in Israel and the territories of the Palestinian authority.
2023 Contracts/Agreements In July, the company entered into an agreement with Lotus Pharmaceuticals to distribute and commercialize VAZKEPA.
2023 Contracts/Agreements In February, the company and Seqirus announced Exclusive License and Distribution agreement for Vazkepa.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Amarin Corp Plc AbbVie Inc GSK plc Acasti Pharma Inc Apotex Inc
Headquarters Ireland United States of America United Kingdom Canada Canada
City Dublin North Chicago Brentford Laval Toronto
State/Province Dublin Illinois England Quebec Ontario
No. of Employees 275 50,000 70,212 32 8,000
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Per Wold-Olsen Chairman Executive Board 2022 74
Patrick J. Holt Chief Executive Officer; Director; President Executive Board 2023 51
Tom Reilly Head - Global HR & Finance; Chief Financial Officer; Executive Vice President Senior Management 2022 52
Steven Ketchum, Ph.D. Executive Vice President; President - Research and Development; Chief Scientific Officer Senior Management 2016 59
Jonathan Provoost Executive Vice President; Chief Legal and Compliance Officer Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Amarin Corp Plc key executives to enhance your sales strategy Gain insight into Amarin Corp Plc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer